Zusammenfassung
Das Sjögren-Syndrom ist eine Autoimmunerkrankung mit lymphozytärer Infiltration der Tränen- und Speicheldrüsen und führt zu Mund- und Augentrockenheit. In der Diagnostik des Sjögren-Syndroms sollte auf extraglanduläre Manifestationen, wie z. B. Polyneuropathie, Arthritis oder gehäufte Atemwegsinfekte, geachtet, die Tränen- und Speichelproduktion gemessen, Antikörper gegen SS-A und SS-B bestimmt und ggf. eine Speicheldrüsenbiopsie durchgeführt werden. Die Behandlung der Mund- und Augentrockenheit erfolgt rein symptomatisch, die der extraglandulären Manifestationen orientiert sich an den entsprechenden Organmanifestationen des systemischen Lupus erythematodes.
Abstract
Sjögren’s syndrome is an autoimmune disease characterized by lymphocytic infiltration of the tear and salivary glands leading to dryness of the mouth and eyes. The awareness that extraglandular manifestations, such as polyneuropathy, arthritis or recurrent airway infections may indicate Sjögren’s syndrome is important. In the diagnostic procedure, the tear and saliva production and antibodies against Sjögren’s syndrome A (SS-A) and SS-B should be measured. A salivary gland biopsy should be performed when the diagnosis is not still clear. The therapy of oral and ocular dryness is mainly symptomatic whereas the treatment of extraglandular manifestations is based on experience with treatment of these manifestations in systemic lupus erythematosus (SLE).
Literatur
Malladi AS, Sack KE, Shiboski SC et al (2012) Primary Sjögren’s syndrome as a systemic disease: a study of participants enrolled in an international Sjögren’s syndrome registry. Arthritis Care Res (Hoboken) 64:911–918
Ramos-Casals M, Solans R, Rosas J et al (2008) Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87:210–219
Foster H, Walker D, Charles P et al (1992) Association of DR3 with susceptibility to and severity of primary Sjögren’s syndrome in a family study. Br J Rheumatol 31:309–314
Foster H, Stephenson A, Walker D et al (1993) Linkage studies of HLA and primary Sjögren’s syndrome in multicase families. Arthritis Rheum 36:473–484
Lessard CJ, Li H, Adrianto I et al (2013) Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren’s syndrome. Nat Genet 45:1284–1292
Shelly S, Boaz M, Orbach H (2012) Prolactin and autoimmunity. Autoimmun Rev 11:A465–A470
Schaumberg DA, Buring JE, Sullivan DA, Dana MR (2001) Hormone replacement therapy and dry eye syndrome. JAMA 286:2114–2119
Triantafyllopoulou A, Tapinos N, Moutsopoulos HM (2004) Evidence for coxsackievirus infection in primary Sjögren’s syndrome. Arthritis Rheum 50:2897–2902
Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM (2006) The role of epithelial cells in the initiation and perpetuation of autoimmune lesions: lessons from Sjogren’s syndrome (autoimmune epithelitis). Lupus 15:255–261
Wahren-Herlenius M, Dörner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382:819–831
Robinson CP, Brayer J, Yamachika S et al (1998) Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren’s syndrome. Proc Natl Acad Sci U S A 95:7538–7543
Pillemer SR, Matteson EL, Jacobsson LT et al (2001) Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 76:593–599
Drosos AA, Andonopoulos AP, Costopoulos JS et al (1988) Prevalence of primary Sjögren’s syndrome in an elderly population. Br J Rheumatol 27:123
Witte T, Matthias T, Bierwirth J, Schmidt RE (2007) Antibodies against alpha-fodrin are associated with sicca syndrome in the general population. Ann N Y Acad Sci 1108:414–417
Schein OD, Hochberg MC, Muñoz B et al (1999) Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 159:1359–1363
Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554–558
Afonso AA, Monroy D, Stern ME et al (1999) Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology 106:803–810
Bijsterveld OP van (1969) Diagnostic tests in the sicca syndrome. Arch Ophthalmol 82:10–14
Wu CH, Hsieh SC, Lee KL et al (2006) Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjögren’s syndrome in Taiwan – a double-blind, placebo-controlled trial. J Formos Med Assoc 105:796–803
Hermann GA, Vivino FB, Goin JE (1999) Scintigraphic features of chronic sialadenitis and Sjögren’s syndrome: a comparison. Nucl Med Commun 20:1123–1132
Aung W, Yamada I, Umehara I et al (2000) Sjögren’s syndrome: comparison of assessments with quantitative salivary gland scintigraphy and contrast sialography. J Nucl Med 41:257–262
García-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine 81:270
Radfar L, Kleiner DE, Fox PC, Pillemer SR (2002) Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis Rheum 47:520–524
Witte T, Matthias T, Arnett FC et al (2000) IgA and IgG autoantibodies against alpha-fodrin as markers for Sjögren’s syndrome. Systemic lupus erythematosus. J Rheumatol 27:2617–2620
Brennan MT, Sankar V, Leakan RA et al (2002) Risk factors for positive minor salivary gland biopsy findings in Sjögren’s syndrome and dry mouth patients. Arthritis Rheum 47:189–195
Cornec D, Jousse-Joulin S, Pers JO et al (2013) Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: toward new diagnostic criteria? Arthritis Rheum 65:216–225
Niemelä RK, Takalo R, Pääkkö E et al (2004) Ultrasonography of salivary glands in primary Sjogren’s syndrome. A comparison with magnetic resonance imaging and magnetic resonance sialography of parotid glands. Rheumatology 43:875–879
Shiboski SC, Shiboski CH, Criswell L et al (2012) American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res 64:475–487
Rasmussen A, Ice JA, Li H et al (2014) Comparison of the American-European Consensus Group Sjogren’s syndrome classification criteria to newly proposed American College of Rheumatology criteria in a large, carefully characterised sicca cohort. Ann Rheum Dis 73:31–38
Vivino FB, Al-Hashimi I, Khan Z et al (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159:174–181
Rihl M, Ulbricht K, Schmidt RE, Witte T (2009) Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren’s syndrome. Rheumatology 48:796–799
Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960–968
Kruize AA, Hené RJ, Kallenberg CG et al (1993) Hydroxychloroquine treatment for primary Sjögren’s syndrome: a two year double blind crossover trial. Ann Rheum Dis 52:360–364
Fox RI, Dixon R, Guarrasi V, Krubel S (1996) Treatment of primary Sjögren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 5(Suppl 1):S31
Gottenberg JE, Ravaud P, Puechal X et al (2013) Inefficacy of hydroxylchloroquine in primary Sjögren’s syndrome: results at 12 months of the randomized placebo-controlled trial of Plaquenil in primary Sjögren’s syndrome. OP0114. Ann Rheum Dis 72(Suppl3):90
Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A et al (2012) Topical and systemic medications for the treatment of primary Sjögren’s syndrome. Nat Rev Rheumatol 8:399–411
Meijer JM, Meiners PM, Vissink A et al (2010) Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:960–968
Gottenberg JE, Cinquetti G, Larroche C et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjogren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis 72:1026–1031
Dass S, Bowman SJ, Vital EM et al (2008) Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 67:1541–1544
Ramos-Casals M, Font J, Garcia-Carrasco M et al (2002) Primary Sjögren syndrome: hematologic patterns of disease expression. Medicine (Baltimore) 81:281
Einhaltung ethischer Richtlinien
Interessenkonflikt. Torsten Witte: Referententätigkeit für die Firmen Roche Pharma AG, AbbVie Deutschland GmbH, GlaxoSmithKline GmbH & Co KG, Chugai Pharma Marketing Ltd, MSD, Sharpe Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, UCB Pharma GmbH. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Witte, T. Sjögren-Syndrom. Z. Rheumatol. 73, 49–61 (2014). https://doi.org/10.1007/s00393-013-1313-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-013-1313-8